Shares of uniQure NV (NASDAQ:QURE) traded up 5.2% during trading on Thursday . The company traded as high as $7.57 and last traded at $7.50, with a volume of 142,544 shares trading hands. The stock had previously closed at $7.13.

A number of analysts recently commented on the stock. Piper Jaffray Cos. restated a “buy” rating on shares of uniQure NV in a research report on Thursday, June 30th. WallachBeth Capital lowered their price objective on shares of uniQure NV from $60.00 to $35.00 and set a “buy” rating for the company in a research report on Wednesday, June 15th. Oppenheimer Holdings Inc. restated an “outperform” rating and issued a $23.00 price objective on shares of uniQure NV in a research report on Wednesday, June 15th. Chardan Capital restated a “buy” rating and issued a $40.00 price objective on shares of uniQure NV in a research report on Wednesday, March 23rd. Finally, Jefferies Group restated a “buy” rating on shares of uniQure NV in a research report on Wednesday, April 6th. One equities research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company. uniQure NV presently has a consensus rating of “Buy” and an average price target of $30.80.

The firm’s 50-day moving average is $9.12 and its 200 day moving average is $12.79. The company’s market capitalization is $182.92 million.

uniQure NV (NASDAQ:QURE) last issued its quarterly earnings results on Tuesday, May 31st. The company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by $0.10. On average, equities analysts expect that uniQure NV will post ($3.14) earnings per share for the current fiscal year.

Uniqure NV is a pharmaceutical company based in the Netherlands. It is primarily engaged in the field of gene therapy for orphan diseases. The Company is focused on patients suffering from genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single administration.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.